A lot of weird bullshit. Have Fun. @mika-13 - Tumblr Blog

The Murderbot Diaries are a power fantasy about being aromantic and still developing extremely important dedicated emotionally intimate partnerships where you are a top priority in a person's life, equal to their other family or romantic attachments despite your own emotional difficulties. And having guns in your arms

blue0909

Please stop being nonbinary too. God only created one gender. You must conform to that.

THERES ONLY ONE NOW?????

miketon

orteil42

evil game design must never be done for money reasons. evil game design must be done for the love of evil itself

beatcroc

almost-correct-quotes

op surely isn't biased here

no-one-offical

‎

pangur-and-grim

I haven't seen people talking about this, but the pilot for The Ebony Witch dropped! the visuals are absolutely beautiful. honestly, it has the same magic as old disney (if disney was brave enough to give us a hot elf who's actually 50 cats in a trenchcoat)

the sound design is a little rough, but that's because of the funding they're working with - if you'd like to lend some support, here's the link!

pangur-and-grim

here's a few screenshots, in case you're not convinced:

erachiiii

Minish!

vampireapologist-archive-deacti

I think a lot about who I am to other people in the world–particular who I am to strangers as a mere concept in their lives.

Today this woman called our information desk and said, “my son’s band is playing tonight. I want to come see him, but he never answers his phone…..I want to be there. Have you heard anything about his band?”

And I felt so bad for this lady but I’m not in the music scene around here so I had to tell her no, sorry.

Five hours later, I’m hiking and run into a group of guys setting up for some outdoor performance, and as I watch them unload the drums it hits me.

“Hey,” I said, “are y’all in a band?”

They said yeah and smiled and I told them “one of your moms called today. She wants to watch you play, but she can’t get a hold of you. Call your mom.”

And they all pulled out their phones and started discussing whose mom it probably was as they presumably dialed their own.

And now, unless we meet again and recognize each other, that’s who I’ll be forever to those guys–some mysterious courier for mom-messages who came out of the woods and told them their mom called.

I didn’t even tell them why their mom called me. Who am I to their mom?? Nobody even asked. They just took my word for it and called their mothers.

Amazing.

vampireapologist-archive-deacti

I’M LAUGHING!!! THEY DIDN’T EVEN ASK WHO I AM.

whyenn-reader

firm believer you can't be a ''good person''. too much niuance to life.

whyenn-reader

you can be good (adjective) but you cannot be good (identity)

whyenn-reader

if you think you are good (identity) you are more likely to cause harm as you don't consider yourself to be capable of it

so1987-deactivated20230102

who’s gonna tell tumblr that executive dysfunction is more than Not Doing Things?

so1987-deactivated20230102

okay

these are the executive functions. impairment of these functions is executive dysfunction

dailypattondoodles

Oh.

lurlur

Girl, help. None of my executives are functioning

deutsche-bahn

Der Kollege ist uns heute Vormittag ins Büro gehüpft. Sollen wir ihn einstellen?

Sofort. Gute Mitarbeiter sind so selten geworden, wenn ihr dem eine Packung Körner auf 'ne Tastatur schüttet kann er sogar Kundenemails beantworten :)

device--conduct

as a vaporeon your only mission in life is to slap your biiiiiiiig damn tail and splash around

device--conduct

as a flareon your only mission in life around is to be fluffy and have an awesome attack stat

device--conduct

as a jolteon your only mission in life is to run around super fuckin fast and be spikey and cool

device--conduct

as an umbreon your only mission on life is to glow and lurch around and go "rrrreaerrr" and stare at stuff with your red eyes

device--conduct

as an espeon your only mission in life is to hear a whole lotta stuff with your big ears and make stuff float and bask in the sun

device--conduct

as a leafeon your only mission in life is to have dope defenses and go around in forests and be cool and green

device--conduct

as a glaceon your only mission in life is to walk around graciously in the cold and lay comfortably in the snow

device--conduct

as a sylveon your only mission in life is to go around joyously and hold onto stuff with your big ribbons and go "(whistling sound)"

device--conduct

as an eevee

evui

wintersoldierfell

you've heard of death of the author, now get ready for death of the audience: where instead of basing your reaction on a thousand uninformed opinions online, you actually read the text and engage with it

wintersoldierfell

girl help there's people on this post who can't actually read my text

reasonsforhope

For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again

For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.

Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time.

-via Science Aim, March 29, 2026.